Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Breath Testing for Rifaximin Response in IBS-D
NCT03729271Phase 4Completed
- Sponsor
- University of Michigan
- Start
- Jan 2020
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in Irritable bowel syndrome with diarrhea (IBS-D), sponsored by University of Michigan. Started Jan 2020; status: completed.
02
Drugs
rifaximin
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT03729271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729271.